Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Thalamic atrophy and cognition in multiple sclerosis.

M K Houtchens1, R H B Benedict, R Killiany

  • 1Department of Neurology, Brigham and Women's Hospital, Harvard Medical School, Partners MS Center, Boston, MA 02115, USA.

Neurology
|September 19, 2007
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Novel cAMP PDE III inhibitors: 1,6-naphthyridin-2(1H)-ones.

Journal of medicinal chemistry·1992
Same author

The development of monoclonal antibodies to the human mitochondrial 60-kd heat-shock protein, and their use in studying the expression of the protein in rheumatoid arthritis.

Arthritis and rheumatism·1992
Same author

Evidence for immunodominance between closely related epitopes in the selection of T cell repertoire: hierarchy of T cell epitopes in a repeating sequence.

Molecular immunology·1992
Same author

Presence of pulmonary intravascular macrophages in the equine lung: some structuro-functional properties.

The Anatomical record·1992
Same author

Prevention of recurrence of insulin-dependent diabetes mellitus in islet cell-transplanted diabetic NOD mice using adjuvant therapy.

Transplantation proceedings·1992
Same author

Structure and hepatoprotective activity of a biflavonoid from Canarium manii.

Planta medica·1992

Thalamic atrophy is significantly more pronounced in multiple sclerosis (MS) patients and strongly correlates with cognitive impairment. This finding highlights thalamic volume as a key biomarker for MS neurodegeneration.

Area of Science:

  • Neuroimaging
  • Neurology
  • Neurodegeneration

Background:

  • Brain atrophy, particularly thalamic involvement, is increasingly recognized as a significant factor in cognitive impairment in multiple sclerosis (MS).
  • Enlargement of the third ventricle in MS patients correlates with cognitive decline, suggesting damage to adjacent structures like the thalamus.

Purpose of the Study:

  • To investigate whether thalamic volume is reduced in MS patients compared to healthy controls.
  • To determine the correlation between thalamic atrophy and cognitive function in individuals with MS.

Main Methods:

  • Utilized three-dimensional MRI scans to segment thalamic volume in 79 MS patients and 16 healthy controls.
  • Assessed cognitive function in a subgroup of 31 MS patients.
  • Quantified whole brain atrophy, third ventricular width, and lesion volumes (T2, T1, and gadolinium-enhanced).

Related Experiment Videos

Main Results:

  • MS patients exhibited significantly lower normalized thalamic volume (16.8% reduction, p < 0.0001) compared to controls.
  • Thalamic volume demonstrated moderate to strong correlations with cognitive performance across all domains (r = 0.506 to 0.724, p < 0.005).
  • Thalamic volume showed a weaker association with physical disability scores (r = -0.316, p = 0.005).

Conclusions:

  • Thalamic atrophy is a significant indicator of the neurodegenerative process in multiple sclerosis.
  • Thalamic volume serves as a clinically relevant biomarker for cognitive impairment in MS.
  • These findings underscore the importance of the thalamus in MS-related neurodegeneration and cognitive decline.